Technical Analysis for CCCC - C4 Therapeutics, Inc.

Grade Last Price % Change Price Change
F 4.05 -2.41% -0.10
CCCC closed down 2.41 percent on Wednesday, November 20, 2024, on 1.36 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
NR7 Range Contraction -2.41%
Narrow Range Bar Range Contraction -2.41%
Lower Bollinger Band Walk Weakness -2.41%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 20 hours ago
Down 5% about 20 hours ago
Down 3% about 23 hours ago
Fell Below Previous Day's Low about 23 hours ago
Down 2 % about 23 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

C4 Therapeutics, Inc. Description

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Treatment Of Cancer Non Small Cell Lung Cancer Melanoma Colorectal Cancer Multiple Myeloma NSCLC Synovial Sarcoma Treatment Of Various Cancers Peripheral T Cell Lymphoma

Is CCCC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.88
52 Week Low 1.06
Average Volume 951,472
200-Day Moving Average 6.43
50-Day Moving Average 5.77
20-Day Moving Average 5.44
10-Day Moving Average 5.01
Average True Range 0.45
RSI (14) 28.06
ADX 23.28
+DI 12.28
-DI 36.60
Chandelier Exit (Long, 3 ATRs) 5.17
Chandelier Exit (Short, 3 ATRs) 5.19
Upper Bollinger Bands 6.90
Lower Bollinger Band 3.97
Percent B (%b) 0.03
BandWidth 53.87
MACD Line -0.44
MACD Signal Line -0.24
MACD Histogram -0.2043
Fundamentals Value
Market Cap 199.59 Million
Num Shares 49.3 Million
EPS -2.75
Price-to-Earnings (P/E) Ratio -1.47
Price-to-Sales 14.89
Price-to-Book 1.28
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.64
Resistance 3 (R3) 4.63 4.43 4.54
Resistance 2 (R2) 4.43 4.28 4.43 4.50
Resistance 1 (R1) 4.24 4.19 4.14 4.25 4.47
Pivot Point 4.04 4.04 3.99 4.04 4.04
Support 1 (S1) 3.85 3.89 3.75 3.86 3.63
Support 2 (S2) 3.65 3.80 3.65 3.60
Support 3 (S3) 3.46 3.65 3.56
Support 4 (S4) 3.47